 MIR-497-HG has been identified as a key regulator of tamoxifen resistance in estrogen receptor-positive breast cancer. It is involved in the activation of PI-3K-AKT signaling pathway, which is essential for cell survival and growth. Depletion of MIR-497-HG leads to tamoxifen resistance by down-regulating the expression of MIR-497-195, which targets five genes involved in PI-3K-AKT signaling. These genes include MAP-2K-1-AKT-3, BCL-2, RAF-1, and CCND-1, all of which are important components of this pathway. Additionally, MIR-497-HG is also involved in epigenetic silencing of these genes via interaction with ZeB1, leading to further tamoxifen resistance. Finally, MIR-497-HG is also regulated by estrogen, suggesting that it may serve as a potential biomarker for predicting tamoxifen sensitivity in patients with ER plus breast cancer. This article was authored by Yao Tian, Zhao Weichen, Peng Wu, and others. We are article.tv, links in the description below.